ArticleRheumatology international2022
COVAD survey 2 long-term outcomes: unmet need and protocol.
Article in Rheumatology international, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Global inequities in biologic and targeted DMARD use in rheumatoid arthritis: cross-sectional data from the international COVAD-2 cohort.Rheumatology international · 2026Article
- The impact of multimorbidity on Quality of Life in inflammatory myopathies: A cluster analysis from the COVAD dataset.Rheumatology (Oxford, England) · 2025Article
- Disease burden in inflammatory arthritis: an unsupervised machine learning approach of the COVAD-2 e-survey dataset.Rheumatology advances in practice · 2025Article
- Determinants of physical function, as measured using PROMIS PF-10a, in patients with rheumatoid arthritis: results from the international COVID-19 Vaccination in Autoimmune Diseases (COVAD) study.Rheumatology advances in practice · 2025Article
- COVID-19 vaccination-related delayed adverse events among people with rheumatoid arthritis: results from the international COVAD survey.Rheumatology international · 2024Article
- Digital Health and Self-Management in Idiopathic Inflammatory Myopathies: A Missed Opportunity?Current rheumatology reports · 2024Review
- Breakthrough SARS-CoV-2 infection in fully vaccinated patients with systemic lupus erythematosus: results from the COVID-19 Vaccination in Autoimmune Disease (COVAD) study.Rheumatology international · 2024Article
- COVID-19 severity, breakthrough infections and vaccine safety in young individuals with autoimmune diseases: insights from the COVAD study.Rheumatology international · 2024Article
- Article
- Impaired health-related quality of life in idiopathic inflammatory myopathies: a cross-sectional analysis from the COVAD-2 e-survey.Rheumatology advances in practice · 2024Article
- Comment on: Impaired health-related quality of life in idiopathic inflammatory myopathies: a cross-sectional analysis from the COVAD-2 e-survey: Reply.Rheumatology advances in practice · 2024Article
- Type 1 diabetes, COVID-19 vaccines and short-term safety: Subgroup analysis from the global COVAD study.Journal of diabetes investigation · 2024Article
- COVID-19 breakthrough infections in type 1 diabetes mellitus: a cross-sectional study by the COVID-19 Vaccination in Autoimmune Diseases (COVAD) Group.Rheumatology international · 2024Article
- COVID-19 Vaccination-Related Delayed Adverse Events among Patients with Systemic Lupus Erythematosus.Journal of clinical medicine · 2023Article
- Delayed adverse events following COVID-19 vaccination in patients with systemic sclerosis and other autoimmune diseases: a substudy of the COVAD-2 cohort.Rheumatology international · 2023Article
- Digital Approaches for Myositis.Current rheumatology reports · 2023Review
- Healthcare utilization and unmet needs of patients with antisynthetase syndrome: An international patient survey.Rheumatology international · 2023Article
- Long-term safety of COVID vaccination in individuals with idiopathic inflammatory myopathies: results from the COVAD study.Rheumatology international · 2023Article
- High fatigue scores in patients with idiopathic inflammatory myopathies: a multigroup comparative study from the COVAD e-survey.Rheumatology international · 2023Article
- Systemic sclerosis and COVID-19 vaccine safety: short-term insights from the global COVID-19 vaccination in autoimmune disease (COVAD) survey.Rheumatology international · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
36 authors.
Funding
Abstract
Vaccine hesitancy is considered a major barrier to achieving herd immunity against COVID-19. While multiple alternative and synergistic approaches including heterologous vaccination, booster doses, and antiviral drugs have been developed, equitable vaccine uptake remains the foremost strategy to manage pandemic. Although none of the currently approved vaccines are live-attenuated, several reports of disease flares, waning protection, and acute-onset syndromes have emerged as short-term adverse events after vaccination. Hence, scientific literature falls short when discussing potential long-term effects in vulnerable cohorts. The COVAD-2 survey follows on from the baseline COVAD-1 survey with the aim to collect patient-reported data on the long-term safety and tolerability of COVID-19 vaccines in immune modulation. The e-survey has been extensively pilot-tested and validated with translations into multiple languages. Anticipated results will help improve vaccination efforts and reduce the imminent risks of COVID-19 infection, especially in understudied vulnerable groups.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.